The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.
Coverage of Aduhelm is now limited to clinical trial participants, meaning that subsidies going to regular patients on Medicare in the US will disappear.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.